Our study revealed a significant decrease in serum adropin levels among patients with SLE compared to healthy controls. The independent association between serum adropin levels and HTN suggests that adropin may serve as a potential predictor of coronary artery disease in individuals with rheumatic diseases. Results deepen our understanding of adropin in SLE, emphasizing its clinical relevance for assessing cardiovascular risk in this population.
Hajialilo et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: